Serum protein fingerprint of patients with gastric cancer by SELDI technology

Abstract

To study the serum protein fingerprint of patients with gastric cancer and to screen for protein molecules closely related to gastric cancer during the onset and progression of the disease using surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Serum samples from 80 gastric cancers and 80 healthy volunteers. WCX2 protein chip and PBSII-C protein chips reader (Ciphergen Biosystems Ins.) were used. The protein fingerprint expression of all the serum samples and the resulting profiles between cancer and normal were analyzed with Biomarker Wizard system. A group of proteomic peaks were detected. Four differently expressed potential biomarkers were identified with the relative molecular weights of 5907, 8678, 11673 and 13725 Da. Among them, two proteins with m/z 8678 and 13725 Da down-regulated, and two proteins with m/z 5907 and 11673 Da were up-regulated in gastric cancers. This diagnostic model can distinguish gastric cancer from healthy controls with a sensitivity of 96% and a specificity of 93.3%. SELDI technology can be used to screen significant proteins of differential expression in the serum of gastric cancer patients.
These different proteins could be specific biomarkers of the patients with gastric cancer in the serum and have the potential value of further investigation.